Compare BRX & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRX | CYTK |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 10.7B |
| IPO Year | 2013 | 2004 |
| Metric | BRX | CYTK |
|---|---|---|
| Price | $27.59 | $65.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 22 |
| Target Price | $35.22 | ★ $109.90 |
| AVG Volume (30 Days) | ★ 2.6M | 1.5M |
| Earning Date | 10-26-2026 | 11-04-2026 |
| Dividend Yield | ★ 4.46% | N/A |
| EPS Growth | ★ 12.61 | N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $1,371,597,000.00 | $13,368,000.00 |
| Revenue This Year | $4.03 | $70.12 |
| Revenue Next Year | $6.16 | $183.63 |
| P/E Ratio | $42.83 | ★ N/A |
| Revenue Growth | ★ 6.73 | N/A |
| 52 Week Low | $24.66 | $54.30 |
| 52 Week High | $32.86 | $88.31 |
| Indicator | BRX | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 27.37 | 35.28 |
| Support Level | $25.89 | $59.05 |
| Resistance Level | $31.17 | $67.04 |
| Average True Range (ATR) | 0.43 | 2.04 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 0.82 | 18.85 |
Brixmor Property Group Inc is a real estate investment trust based in the United States. The company owns and operates a portfolio of grocery-anchored community and neighborhood shopping centers across the United States. It leases its rentable areas to retailers, restaurants, theatres, entertainment venues, and fitness centers, with the company's tenants consisting of large department stores, discount retailers, and grocery stores. The company is an internally managed REIT. The company operates in Florida, Texas, California, New York, Pennsylvania, Illinois, New Jersey, Georgia, North Carolina, Michigan, Ohio and other states.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.